PDA Technical Report No. 82 (TR 82) serves as the industry standard for investigating Low Endotoxin Recovery (LER) in biologics, guiding manufacturers on evaluating potential false-negative endotoxin tests. Published in 2019, the report dictates specific methodologies for hold-time studies and is widely accepted by regulatory bodies like the FDA and EMA. While recognized as the benchmark for compliance, the Parenteral Drug Association (PDA) is currently revising the document to address challenges in execution and scientific advancements. For more details, visit the Parenteral Drug Association www.linkedin.com Alessandro Pauletto - European Medicines Agency (EMA)
The PDA first published Technical Report 82 in 2015, with the aim of providing a detailed framework for evaluating sterile compounding facilities. The report was developed by a team of experts with extensive experience in sterile compounding, facility design, and regulatory compliance. TR 82 provides guidance on the key elements of sterile compounding facilities, including design, construction, and operation. pda technical report 82
TR 82 is divided into several sections, each addressing a critical aspect of sterile compounding facilities. The report covers the following key components: PDA Technical Report No
Before discussing the solution, one must understand the problem. LER refers to the inability to recover detectable endotoxin activity from a sample matrix even though endotoxin has been intentionally spiked into that matrix. While recognized as the benchmark for compliance, the
It sounds like you’re looking for a from PDA Technical Report No. 82 (TR-82) , titled “Low Endotoxin Recovery” (published 2020).